Dr. Donald C. Rio's lab at UC Berkeley focuses on understanding DNA transposons and their roles in gene expression, especially through a process called alternative pre-mRNA splicing. Their research explores how these mobile genetic elements impact human health and development, including their contributions to diseases like ALS. By studying these processes in model organisms like Drosophila and through advanced techniques like cryo-electron microscopy, the lab aims to uncover critical insights into gene regulation that could lead to biomedical advancements.

Dr. Sarah A. Stanley's lab focuses on understanding how the bacteria Mycobacterium tuberculosis (Mtb) suppresses the human immune system, which allows for chronic infections. The lab investigates two key components, the ESX-1 secretion system and a lipid called PDIM, to see how they work together to evade the immune response. By studying these mechanisms in mouse models, the lab aims to uncover new potential therapies to combat tuberculosis, one of the deadliest infectious diseases.

Dr. Michel Dupage's lab focuses on understanding how regulatory T cells (Tregs) hinder the effectiveness of cancer immunotherapies. By studying the mechanisms through which Tregs suppress the immune response within tumors, the lab aims to develop targeted therapies that can enhance anti-tumor immunity while minimizing autoimmune side effects. This research is crucial for improving cancer treatment options and making immunotherapies more effective for patients.

Dr. Jay D. Keasling's lab focuses on developing improved vaccines by designing better adjuvants, which are substances that enhance the immune response to vaccine antigens. The research combines synthetic biology techniques to engineer yeast for adjuvant production with systems immunology to understand how these adjuvants work at the molecular level. This interdisciplinary approach aims to create innovative solutions for preventing and treating diseases.

Dr. Russell E. Vance's lab at UC Berkeley focuses on understanding how the bacteria Shigella causes disease. By developing a new mouse model that mimics human infection, the lab investigates the immune response and key cellular players that contribute to disease severity and resolution. Their research has significant implications for public health, particularly in combatting diarrheal diseases that affect millions worldwide.